| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7569612 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(3 years from now) | |
| US7741374 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(3 years from now) | |
| US7741373 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(3 years from now) | |
| US7915247 | ATHENA | Methods of use of fenofibric acid |
Aug, 2027
(3 years from now) | |
Fibricor is owned by Athena.
Fibricor contains Fenofibric Acid.
Fibricor has a total of 4 drug patents out of which 0 drug patents have expired.
Fibricor was authorised for market use on 14 August, 2009.
Fibricor is available in tablet;oral dosage forms.
Fibricor can be used as adjunctive therapy to diet in patients with hyperlipidemias; adjunctive therapy to diet in patients with mixed dyslipidemia; adjunctive therapy to diet to patients with hypertriglyceridemia, adjunctive therapy to diet to patients with hypertriglyceridemia, adjunctive therapy to diet in patients with hyperlipidemias, adjunctive therapy to diet in patients with mixed dyslipidemia; adjunctive therapy to diet in patients with elevated cholesterol and/or lipid levels.
The generics of Fibricor are possible to be released after 20 August, 2027.
Drugs and Companies using FENOFIBRIC ACID ingredient
Market Authorisation Date: 14 August, 2009
Treatment: Adjunctive therapy to diet in patients with hyperlipidemias; Adjunctive therapy to diet in patients with mixed dyslipidemia; Adjunctive therapy to diet in patients with elevated cholesterol and/or lip...
Dosage: TABLET;ORAL
FIBRICOR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic